Prime

Type your tag names separated by a space and hit enter

Hypothyroidism is a Risk Factor for New-Onset Diabetes: A Cohort Study.

Abstract

OBJECTIVE

To identify risk factors for the development of statin-associated diabetes mellitus (DM).

RESEARCH DESIGN AND METHODS

The study was conducted in two phases. Phase one involved high-throughput in silico processing of a large amount of biomedical data to identify risk factors for the development of statin-associated DM. In phase two, the most prominent risk factor identified was confirmed in an observational cohort study at Clalit, the largest health care organization in Israel. Time-dependent Poisson regression multivariable models were performed to assess rate ratios (RRs) with 95% CIs for DM occurrence.

RESULTS

A total of 39,263 statin nonusers were matched by propensity score to 20,334 highly compliant statin initiators in 2004-2005 and followed until the end of 2010. Within 59,597 statin users and nonusers in a multivariable model, hypothyroidism and subclinical hypothyroidism carried an increased risk for DM (RR 1.53 [95% CI 1.31-1.79] and 1.75 [1.40-2.18], respectively). Hypothyroidism increased DM risk irrespective of statin treatment (RR 2.06 [1.42-2.99] and 1.66 [1.05-2.64] in statin users and nonusers, respectively). Subclinical hypothyroidism risk for DM was prominent only upon statin use (RR 1.94 [1.13-3.34] and 1.20 [0.52-2.75] in statin users and nonusers, respectively). Patients with hypothyroidism treated with thyroid hormone replacement therapy were not at increased risk for DM.

CONCLUSIONS

Hypothyroidism is a risk factor for DM. Subclinical hypothyroidism-associated risk for DM is prominent only upon statin use. Identifying and treating hypothyroidism and subclinical hypothyroidism might reduce DM risk. Future clinical studies are needed to confirm the findings.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Pharmacoepidemiology and Pharmacogenetics Unit, Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel gronichn@clalit.org.il.

    ,

    Biovista Inc., Charlottesville, VA.

    ,

    Pharmacoepidemiology and Pharmacogenetics Unit, Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.

    ,

    Biovista Inc., Charlottesville, VA.

    ,

    Drug Safety Group, Office of Clinical Pharmacology, U.S. Food and Drug Administration, Silver Spring, MD.

    Pharmacoepidemiology and Pharmacogenetics Unit, Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.

    Source

    Diabetes care 38:9 2015 Sep pg 1657-64

    MeSH

    Adult
    Aged
    Aged, 80 and over
    Cohort Studies
    Diabetes Mellitus, Type 2
    Female
    Humans
    Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Hypothyroidism
    Israel
    Male
    Middle Aged
    Propensity Score
    Risk Factors

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    26070591

    Citation

    TY - JOUR T1 - Hypothyroidism is a Risk Factor for New-Onset Diabetes: A Cohort Study. AU - Gronich,Naomi, AU - Deftereos,Spyros N, AU - Lavi,Idit, AU - Persidis,Andreas S, AU - Abernethy,Darrell R, AU - Rennert,Gad, Y1 - 2015/06/12/ PY - 2014/10/23/received PY - 2015/5/21/accepted PY - 2015/6/12/aheadofprint PY - 2015/6/14/entrez PY - 2015/6/14/pubmed PY - 2016/3/29/medline SP - 1657 EP - 64 JF - Diabetes care JO - Diabetes Care VL - 38 IS - 9 N2 - OBJECTIVE: To identify risk factors for the development of statin-associated diabetes mellitus (DM). RESEARCH DESIGN AND METHODS: The study was conducted in two phases. Phase one involved high-throughput in silico processing of a large amount of biomedical data to identify risk factors for the development of statin-associated DM. In phase two, the most prominent risk factor identified was confirmed in an observational cohort study at Clalit, the largest health care organization in Israel. Time-dependent Poisson regression multivariable models were performed to assess rate ratios (RRs) with 95% CIs for DM occurrence. RESULTS: A total of 39,263 statin nonusers were matched by propensity score to 20,334 highly compliant statin initiators in 2004-2005 and followed until the end of 2010. Within 59,597 statin users and nonusers in a multivariable model, hypothyroidism and subclinical hypothyroidism carried an increased risk for DM (RR 1.53 [95% CI 1.31-1.79] and 1.75 [1.40-2.18], respectively). Hypothyroidism increased DM risk irrespective of statin treatment (RR 2.06 [1.42-2.99] and 1.66 [1.05-2.64] in statin users and nonusers, respectively). Subclinical hypothyroidism risk for DM was prominent only upon statin use (RR 1.94 [1.13-3.34] and 1.20 [0.52-2.75] in statin users and nonusers, respectively). Patients with hypothyroidism treated with thyroid hormone replacement therapy were not at increased risk for DM. CONCLUSIONS: Hypothyroidism is a risk factor for DM. Subclinical hypothyroidism-associated risk for DM is prominent only upon statin use. Identifying and treating hypothyroidism and subclinical hypothyroidism might reduce DM risk. Future clinical studies are needed to confirm the findings. SN - 1935-5548 UR - https://www.unboundmedicine.com/medline/citation/26070591/full_citation L2 - http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=26070591 ER -